Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04910217Not ApplicableUnknown

Robot-Assisted Gait Therapy in the Subacute Phase of First Ischemic Stroke

Role: collaborator

NCT05197543Unknown

AAA Rupture Risk Assessment in COVID-19 Pandemic

Role: collaborator

NCT02270125Completed

Nanoparticles in Nasal Mucosa

Role: collaborator

All 3 trials loaded